Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer".

Cancer research - 1 Aug 2016

Benjamin Laura E

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colorectal Neoplasms

Share to Proto-Oncogene Proteins

Share to ras Proteins

Source

Identifiers

PMID: 27480959
DOI: 10.1158/0008-5472.CAN-16-1871

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer".PMID 27480959Read ↗

KRAS status predicts response to cetuximab for metastatic colorectal cancer.Semantic proximity Read ↗

Author response to: Comment on: KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations.Semantic proximity Read ↗

Letter to the editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation.Semantic proximity Read ↗

Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.Semantic proximity Read ↗

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.Semantic proximity Read ↗

KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.Semantic proximity Read ↗

Genetics: Predictive value of KRAS mutations in chemoresistant CRC.Semantic proximity Read ↗

KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.Semantic proximity Read ↗

KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer.Semantic proximity Read ↗

Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.